(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Pick the Right Old Consideration Administration: Key Contemplations - 2The Manual for Electric Vehicles that will be hot dealers in 2023
- 3Favored Chinese Dish: Make Your Determination
- 4See the famous winged horse Pegasus fly in the autumn night sky
- 5US FDA approves Kura-Kyowa's blood cancer therapy
- This Week In Space podcast: Episode 186 — Snow on the Moon?
- Finding Europe's Head Traveler Objections: An Excursion Through Famous Attractions
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- 7 Logically Demonstrated Techniques for Better Rest
- Medical team successfully delivers baby and removes massive tumor
- Vote in favor of the wide open action that revives your brain and soul!
- Your big brain makes you human – count your neurons when you count your blessings
- The Best Cell phone Brands for Tech Aficionados
